Skip to main content
Ascelia Pharma logo

Ascelia Pharma — Investor Relations & Filings

Ticker · ACE ISIN · SE0010573113 LEI · 5493002YR9VCJJPWYN08 ST Manufacturing
Open in API
Filings indexed 295 across all filing types
Latest filing 2020-04-06 Annual Report
Country SE Sweden
Listing ST ACE

About Ascelia Pharma

https://www.ascelia.com/

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.

Recent filings

Filing Released Lang Actions
Annual Report 2019
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2019' and covers the period from 1 July 2019 to 31 December 2019. It contains comprehensive sections typical of an annual report, including CEO comments, strategy, director's reports, corporate governance, and full consolidated financial statements (Income Statement, Balance Sheet, Cash Flow, etc.). It is clearly a formal annual financial report rather than an announcement or a summary. FY 2019
2020-04-06 English
KALLELSE TILL ÅRSSTÄMMA I ASCELIA PHARMA AB
AGM Information Classification · 98% confidence The document is titled "KALLELSE TILL ÅRSSTÄMMA I ASCELIA PHARMA AB" which translates to "NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB". It details the date, time, location, procedures for participation (including COVID-19 precautions), voting rights, and the proposed agenda for the meeting. The agenda items (e.g., election of chairman, approval of financial statements, determination of board fees, election of directors, remuneration guidelines) are characteristic of an Annual General Meeting (AGM) notice. Although it mentions the Annual Report (item 7 on the agenda), the document itself is the formal notice and proposal document for the meeting, which aligns best with the AGM-R (AGM Information) category, as it contains the materials and context for the meeting itself, rather than being the full 10-K or a simple announcement of a report release (RPA).
2020-04-03 Swedish
NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB
AGM Information Classification · 100% confidence The document is explicitly titled "NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB" and details the date, location, agenda items (including election of directors, approval of reports, remuneration, and share incentive programs), and proposed resolutions for this meeting. This content is the core material distributed to shareholders in preparation for an Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R). The document length is substantial (over 4,600 characters), confirming it is the primary material, not just a brief announcement of publication (RPA).
2020-04-03 English
Correction to press release regarding in change in number of shares and votes in Ascelia Pharma AB
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a short press release correcting a previously issued statement regarding the 'number of shares and votes' in the company. It explicitly details the corrected total number of shares and the breakdown of ordinary vs. series C shares, along with the resulting total number of votes. This directly relates to changes in the company's capital structure or share count. Based on the definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate category for announcements detailing changes in the total number of shares outstanding. Although it is a correction, the core subject matter is the share count.
2020-04-01 English
Korrektion till pressmeddelande om ändring av antalet aktier och röster i Ascelia Pharma AB
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release dated April 1, 2020, titled "Korrektion till pressmeddelande om ändring av antalet aktier och röster i Ascelia Pharma AB" (Correction to press release regarding change in the number of shares and votes in Ascelia Pharma AB). It explicitly corrects a previous announcement regarding the number of C-shares issued and states the resulting total number of shares and votes as of March 31, 2020. This content directly relates to changes in the company's capital structure (share count and voting rights). This aligns best with the 'Share Issue/Capital Change' definition (SHA), which covers announcements regarding new share issues or capital changes. It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a dividend notice (DIV) or director dealing (DIRS).
2020-04-01 Swedish
Ändring av antalet aktier och röster i Ascelia Pharma AB
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release dated March 31, 2020, titled "Ändring av antalet aktier och röster i Ascelia Pharma AB" (Change in the number of shares and votes in Ascelia Pharma AB). It explicitly details an increase in the number of shares due to a directed new share issue and subsequent repurchase of C-shares, resulting in a new total count of shares and votes as of that date. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). It is not a general regulatory filing (RNS) because it is highly specific to capital structure changes.
2020-03-31 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.